Know Cancer

or
forgot password

A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)


Phase 2
18 Years
N/A
Not Enrolling
Both
Myelodysplastic Syndromes, Anemia

Thank you

Trial Information

A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)


This is a randomized (patients are assigned to a type of treatment by chance), open-label
(both the patient and the physician know what treatment is being given), multi-center study
in approximately 100 anemic patients with Low- or Intermediate-1 risk Myelodysplastic
Syndromes (MDS). Patients with a diagnosis of MDS via bone marrow aspirate and biopsy
according to World Health Organization (WHO) Criteria or French-American-British (FAB)
Classification, and International Prognostic Scoring System (IPSS) of Low- or Intermediate-1
risk disease (<=10% bone marrow blasts), a baseline hemoglobin (Hb) < 10.0 g/dL [defined as
the average of at least 2 measurements (not influenced by red blood cell (RBC) transfusions
for at least 1 week) greater than or equal to 1 week apart], and who meet all other
inclusion/exclusion criteria will be randomized to receive PROCRIT (Epoetin alfa) 80,000
Units under the skin (sc) once weekly (qw ) or 80,000 Units sc once every 2 weeks (q2w).

The total study duration is up to 30 weeks, including up to a 2-week screening phase, a
24-week dosing phase, a follow-up visit according to the patient's assigned visit schedule,
and a 4-week safety follow-up phase.

Beginning at Week 13, and every week thereafter, patients will be assessed for Erythroid
Response. Overall Erythroid Response (OER) (as per the 2000 International Working Group
(IWG) Criteria) including Major and Minor Erythroid Responses is defined as: Major Erythroid
Response: Having sustained one of the following criteria over a minimum of 8 weeks: >2 g/dL
rise in hemoglobin (Hb), OR transfusion independence for patients who were RBC transfusion
dependent (defined as requiring 4 or more red blood cell (RBC) units within 8 weeks prior to
the first dose of PROCRIT (Epoetin alfa) ) at baseline. Minor Erythroid Response is defined
as: Having sustained one of the following criteria over a minimum of 8 weeks: 1-2 g/dL rise
in Hb, OR 50 to <100% transfusion reduction for patients who were RBC transfusion dependent
(defined as requiring 4 or more RBC units within 8 weeks prior to the first dose of PROCRIT
(Epoetin alfa)) at baseline.

Overall Erythroid Response (OER) (as per the 2006 Modified IWG Criteria) is one of the
secondary endpoints of the study and is defined as: Having sustained one of the following
criteria over a minimum of 8 weeks: >= 1.5 g/dL rise in Hb, OR Reduction in transfusion
requirements by at least 4 RBC units for patients who were RBC transfusion dependent
(defined as requiring 4 or more RBC units within 8 weeks prior to the first dose of PROCRIT
(Epoetin alfa) at baseline. Only RBC transfusions given for a Hb of <= 9.0 g/dL
pretreatment will count in the RBC transfusion response evaluation.

Fatigue assessments [Brief Fatigue Inventory (BFI) and Medical Outcome Survey (MOS) Short
Form-36 (SF-36)] will be completed by patients at baseline (Day 1/Week 1), Week 9, Week 13,
and at end of study. In addition, a Global Rating of Change in Level of Fatigue
(single-item question) will be completed by patients at Week 13 and end of study.

Safety evaluations will be performed at specified intervals during the study. Hb,
hematocrit (Hct), and blood pressure will be monitored weekly. Clinical safety will be
assessed by the incidence and severity of adverse events, clinical laboratory tests (Hb and
Hct), vital signs and physical examinations during the study period.

Patients will be randomized in a 1:1 ratio to receive PROCRIT (Epoetin alfa) 80,000 Units
given under the skin once a week or 80,000 Units given under the skin once every 2 weeks.
Dose adjustments will be made (i.e., dose increased or decreased, frequency decreased, or
doses withheld) in response to Hb monitoring throughout the study and in order to maintain a
Hb level in the target range of 11 to 12 g/dL.


Inclusion Criteria:



- Diagnosis of Myelodysplastic Syndromes (MDS) via bone marrow aspirate and biopsy
according to World Health Organization (WHO) Criteria or French-American-British
(FAB) Classification. All WHO and FAB subtypes of MDS are potentially eligible,
provided the subject's International Prognostic Scoring System (IPSS) score is Low-
or Intermediate-1 [with the exception of chronic myelomonocytic leukemia (CMML)]

- Documentation of IPSS score of Low- or Intermediate-1 risk disease (<= 10% bone
marrow blasts), based on bone marrow aspirate, biopsy, and cytogenetics, within 12
weeks prior to study entry

- Baseline hemoglobin (Hb) value of <10 g/dL [defined as the average of at least 2
measurements [(not influenced by red blood cell (RBC) transfusions for at least 1
week) >= 1 week apart]. The Hb level prior to the first dose of PROCRIT (Epoetin
alfa) cannot be > 10.5 g/dL.

Exclusion Criteria:

- No anemia due to factors other than MDS (including hemolysis or gastrointestinal
bleeding)

- No proliferative (White Blood Cells (WBC) >= 12,000/mm3) chronic myelomonocytic
leukemia (CMML)

- No history of (within 12 months) deep venous thrombosis [(DVT), includes proximal and
distal], pulmonary embolism (PE), or other venous thrombosis. Prior superficial
thrombophlebitis is not an exclusion criterion

- No history of (within 6 months) cerebrovascular accident [(CVA), includes ischemic,
embolic and hemorrhagic], transient ischemic attack (TIA), myocardial ischemia
[includes Unstable Angina, Q wave Myocardial Infarction (QwMI) and non-Q wave
Myocardial Infarction (NQMI)], or other arterial thrombosis

- No prior Erythropoietin Receptor Agonist (ERA) treatment within 4 weeks prior to the
first study dose

- No prior ERA treatment failure (defined as having shown no Hb response or a Hb
response <1 g/dL after at least 6 weeks of ERA treatment) with minimum dose of
Epoetin alfa 40,000 Units/week or Darbepoetin alfa 150 mcg/ week.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary efficacy endpoint is the proportion of patients (POP) in each treatment group achieving an Overall Erythroid Response (OER) [as per the 2000 International Working Group (IWG) Criteria] by Week (Wk) 13 of the study.

Principal Investigator

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial

Investigator Role:

Study Director

Investigator Affiliation:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Authority:

United States: Food and Drug Administration

Study ID:

CR013198

NCT ID:

NCT00446602

Start Date:

Completion Date:

August 2009

Related Keywords:

  • Myelodysplastic Syndromes
  • Anemia
  • PROCRIT
  • Epoetin alfa
  • Myelodysplastic Syndromes
  • MDS
  • Anemia
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location